Literature DB >> 9759873

Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR.

D G Doherty1, J E Penzotti, D M Koelle, W W Kwok, T P Lybrand, S Masewicz, G T Nepom.   

Abstract

TCR engagement of peptide-MHC class II ligands involves specific contacts between the TCR and residues on both the MHC and peptide molecules. We have used molecular modeling and assays of peptide binding and T cell function to characterize these interactions for a CD4+ Th1 cell clone, ESL4.34, which recognizes a peptide epitope of the herpes simplex type 2 virus virion protein, VP16 393-405, in the context of several HLA-DR alleles. This clone responded to VP16 393-405 in proliferation and cytotoxicity assays when presented by DRB1*0402, DRB1*1102, and DRB1*1301, which share a common amino acid sequence, ILEDE, at residues 67-71 in the alpha-helical portion of the DRbeta polypeptide, but not when presented by other DR4, DR11, and DR13 alleles that are negative for this sequence. Using a panel of APCs expressing DR4 molecules that were mutagenized in vitro at individual residues within this shared epitope and using peptide analogues with single amino acid substitutions of predicted MHC and TCR contact residues, a unit of recognition was identified dependent on DRbeta residues 67-71 and relative position 4 (P4) of the VP16 393-405 peptide. The interactions of this portion of the peptide-DR ligand with the ESL4.34 TCR support a structural model for MHC-biased recognition in some Ag-specific and alloreactive T cell responses and suggest a possible mechanism for autoreactive T cell selection in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759873

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

2.  Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype.

Authors:  Mireia Sospedra; Paolo A Muraro; Irena Stefanová; Yingdong Zhao; Katherine Chung; Yili Li; Marc Giulianotti; Richard Simon; Roy Mariuzza; Clemencia Pinilla; Roland Martin
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 4.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

5.  A real-time PCR approach for rapid high resolution subtyping of HLA-DRB1*04.

Authors:  Vivian H Gersuk; Gerald T Nepom
Journal:  J Immunol Methods       Date:  2006-10-02       Impact factor: 2.303

6.  Analysis of cortical thickness in narcolepsy patients with cataplexy.

Authors:  Eun Yeon Joo; Seun Jeon; Minjoo Lee; Sung Tae Kim; Uicheul Yoon; Dae Lim Koo; Jong-Min Lee; Seung Bong Hong
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

Review 7.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 8.  Diagnosis and management of the overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

Review 9.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

10.  Gray matter concentration abnormality in brains of narcolepsy patients.

Authors:  Eun Yeon Joo; Woo Suk Tae; Sung Tae Kim; Seung Bong Hong
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.